Method for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US8227420B2 · kind B2 · utility
9Cited by
49References
34Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 9, 2010 |
| Grant date | Jul 24, 2012 |
| Priority date | — |
| Expiry date | Mar 9, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to compositions and methods for treating immune system diseases such as rheumatic disease, by administering to a subject soluble CTLA4 molecules that block endogenous B7 molecules from binding their ligands, alone, or in conjunction with other agents including Disease Modifying Anti-Rheumatic Drugs (DMARDs).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.